QUANtification of Cardiovascular Autonomic Neuropathy (CAN) and the effects of anaesthesia on hemodynamics and cerebral perfusio

Completed

• Conditions: Autonomic neuropathy as a result of diabetes; cardiovascular autonomic neuropathy; 10012653

• Registration Number: NL-OMON46328
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 45

Inclusion Criteria

Willing and able to give written informed consent, scheduled for elective, non-cardiothoracic surgery under general anesthesia and age 18 years and above

Exclusion Criteria

Day case surgery, laparoscopic procedure, DM type 1, Parkinson*s disease, uncontrolled cardiac arrhythmia, Pure autonomic failure (formerly called idiopathic orthostatic hypotension), Multiple system atrophy with autonomic failure (formerly called Shy-Drager syndrome), Addison*s disease and hypopituitarism, pheochromocytoma, peripheral autonomic neuropathy (e.g., amyloid neuropathy, idiopathic autonomic neuropathy), known cardiomyopathy, extreme left ventricle hypertrophy or ejection fraction < 30%, proven or suspected allergy for any of the medication used during induction of anaesthesia, malignant hyperthermia, unability to record transcranial doppler ultrasound due to anatomical variance.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Between group difference in hemodynamic parameters and cerebral perfusion<br /><br>parameters.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Determine the relationship between autonomic function tests and clinical<br /><br>outcome during 30-postoperative days (observational). Outcome measures include<br /><br>frequency of all adverse and serious adverse events.</p><br>